Kidney Donation Compatibility: Understanding Donor-Recipient Matching

Determining Compatibility for Kidney Transplantation

Kidney transplantation requires careful matching between donor and recipient to minimize rejection and maximize graft survival. Compatibility is assessed through multiple, complementary evaluations:

1. ABO Blood Group Compatibility

  • Donor and recipient must have compatible ABO blood types (identical or compatible, e.g., O to any, A to A/AB, B to B/AB, AB to AB).
  • ABO-incompatible transplants are possible with desensitization protocols (plasmapheresis, IVIG, rituximab) but carry higher risk.
  • Rh factor does not affect kidney transplant compatibility.

2. HLA Tissue Typing (Human Leukocyte Antigen Matching)

  • HLA-A, -B, -DR loci are typed for both parties.
  • Better matching (fewer mismatches) correlates with lower rejection rates and longer graft survival, especially for living donor transplants.
  • Modern immunosuppression has reduced the absolute requirement for close HLA matching.

3. Crossmatch Testing

  • Complement-dependent cytotoxicity (CDC) crossmatch and flow cytometry crossmatch detect preformed anti-donor antibodies in the recipient.
  • A negative crossmatch (no donor-specific antibodies) is required for proceeding without desensitization.
  • A positive crossmatch indicates high risk of hyperacute or accelerated rejection.

4. Donor Evaluation

  • Comprehensive medical, surgical, and psychosocial assessment.
  • Exclusion criteria: uncontrolled hypertension, diabetes, significant proteinuria, GFR <80 mL/min, active malignancy, infections, psychiatric instability.
  • Imaging (CT angiography) to evaluate renal anatomy and vascular suitability.

5. Living vs. Deceased Donor

  • Living donor: Preferred—better organ quality, shorter cold ischemia time, planned surgery, superior long-term outcomes.
  • Deceased donor: Allocated via waiting list (e.g., UNOS/KDPI in US); includes donation after brain death (DBD) and circulatory death (DCD).

6. Ethical and Legal Framework

  • Informed, voluntary consent; no coercion or financial incentive.
  • Independent donor advocate team.
  • Compliance with national regulations (e.g., NOTA in US, Human Tissue Act in UK).

7. Recipient Suitability

  • Absence of active infection, uncontrolled malignancy, severe irreversible cardiac/pulmonary/hepatic disease.
  • Adequate social support and adherence capacity for lifelong immunosuppression.

8. Long-Term Follow-Up

Both donor and recipient require lifelong monitoring: graft function (creatinine, eGFR), immunosuppression levels, metabolic complications, cancer screening, and quality of life. Donor follow-up includes annual renal function and blood pressure checks.

Kidney Disease - Related Articles